Lung Neoplasms
|
0.510 |
Biomarker
|
group |
CTD_human |
DNA methylation markers and early recurrence in stage I lung cancer.
|
18337602 |
2008 |
Lung Neoplasms
|
0.510 |
Biomarker
|
group |
RGD |
Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway.
|
17971904 |
2007 |
Lung Neoplasms
|
0.510 |
PosttranslationalModification
|
group |
LHGDN |
p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.
|
16222700 |
2006 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
RT-PCR was used to measure CDH13 expression in lung cancer A549 and A549/DDP cells with or without 5-Aza-CdR intervention.
|
30344726 |
2018 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Quantitative assessment of the diagnostic role of CDH13 promoter methylation in lung cancer.
|
25735345 |
2015 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
CTD_human |
DNA methylation markers and early recurrence in stage I lung cancer.
|
18337602 |
2008 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The methylation status of 6 genes, including a candidate tumor suppressor gene (BLU), the cadherin 13 gene (CDH13), the fragile histidine triad gene (FHIT), the cell cycle control gene p16, the retinoic acid receptor beta gene (RARbeta), and the Ras association domain family 1 gene (RASSF1A), was examined in plasma samples, corresponding tumor tissues, and normal lung tissues from a group of 63 patients with lung cancer and in plasma samples from 36 cancer-free individuals.
|
17876837 |
2007 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The methylation status of the promoter regions of the E-cadherin and H-cadherin genes was examined by using nested MSP in 88 primary lung cancers and paired adjacent normal tissues.
|
17960794 |
2007 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, the frequency of p16INK4A or CDH13 hypermethylation in patient serum, together with evidence of their early occurrence in lung cancerogenesis and the total lack of methylation in serum from healthy individuals, offer a promising tool for non invasive early detection of lung cancer.
|
16222700 |
2006 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation status of p16(INK4a), RASSF1A, APC, RARbeta, and CDH13, frequently methylated in lung cancer, was determined by methylation-specific PCR and the degree of methylation was defined as the methylation index.
|
16452191 |
2006 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study examined the relationship between methylation of five genes (p16(INK4a), RASSF1A, APC, RARbeta and CDH13) and patient survival in 351 cases of surgically resected lung cancers.
|
15266335 |
2004 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined 514 cases of NSCLC and 84 corresponding nonmalignant lung tissues from 4 countries (USA, Australia, Japan and Taiwan) for the methylation status of 7 genes known to be frequently methylated in lung cancers [p16, RASSF1A (RAS association domain family 1), APC, RARbeta, CDH13, MGMT and GSTP1].
|
12455028 |
2003 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Previously, we reported that the 5' region of CDH13 is frequently methylated in breast and lung cancers.
|
12067979 |
2002 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We examined the methylation status of the CDH13 promoter in breast and lung cancers and correlated it with mRNA expression using methylation-specific PCR and reverse transcription-PCR.
|
11389090 |
2001 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We determined the frequency of aberrant promoter methylation of the p16, adenomatous polyposis coli (APC), H-cadherin (CDH13), glutathione S-transferase P1 (GSTP1), O6-methylguanine-DNA-methyltransferase (MGMT), retinoic acid receptor beta-2 (RAR beta), E-cadherin (CDH1), and RAS association domain family 1A (RASSF1A) genes in 198 tumors consisting of small cell lung cancers [SCLCs (n = 43)], non-small cell lung cancers [NSCLCs (n = 115)], and bronchial carcinoids (n = 40).
|
12467239 |
2001 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
These results suggest that a combination of deletion and hypermethylation causes inactivation of the CDH13 gene in a considerable number of human lung cancers.
|
9737784 |
1998 |
Non-Small Cell Lung Carcinoma
|
0.380 |
PosttranslationalModification
|
disease |
BEFREE |
The rate of RASSF1A and CDH13 gene methylation in 42 cases of NSCLC patients was significantly higher than in 40 healthy controls (52.4% to 0.0%, 54.8% to 0.0%, p<0.05).
|
24998565 |
2014 |
Non-Small Cell Lung Carcinoma
|
0.380 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant methylation in CDH13 and MGMT was associated with clinicopathologic features of NSCLC.
|
22169480 |
2012 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
CTD_human |
Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.
|
18337602 |
2008 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
In a multivariate model, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene p16, the H-cadherin gene CDH13, the Ras association domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of NSCLC stage, age, sex, race, smoking history, and histologic characteristics of the tumor.
|
18337602 |
2008 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
The authors investigated the methylation status of the promoter region of human E-cadherin and H-cadherin genes in resected samples of primary nonsmall cell lung cancer (NSCLC) using methylation-specific polymerase chain reaction (MSP) analysis and correlated the results with clinicopathologic characteristics.
|
17960794 |
2007 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
In the present study, promoter hypermethylation of p16INK4A and CDH13 genes was investigated in tumor tissue and in matched serum from 61 patients with histologically confirmed non-small cell lung cancer.
|
16222700 |
2006 |
Non-Small Cell Lung Carcinoma
|
0.380 |
PosttranslationalModification
|
disease |
BEFREE |
We determined the methylation of p16, CDH13 and RAR-beta which were reported to be methylated frequently in NSCLCs and HPP-1 which was known to be methylated in other types of cancers.
|
15201980 |
2004 |
Non-Small Cell Lung Carcinoma
|
0.380 |
PosttranslationalModification
|
disease |
BEFREE |
We examined 514 cases of NSCLC and 84 corresponding nonmalignant lung tissues from 4 countries (USA, Australia, Japan and Taiwan) for the methylation status of 7 genes known to be frequently methylated in lung cancers [p16, RASSF1A (RAS association domain family 1), APC, RARbeta, CDH13, MGMT and GSTP1].
|
12455028 |
2003 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).
|
12174885 |
2002 |